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15.1
Shift in IgG subclasses - a tissue non specific tumor marker in patients
with squamous cell carcinoma of the head and neck
W. Anderhuber, W. Steinschifter', E. Schauenstein', K. Schauenstein2, A.
Gotschuli, Depts. of ORL, 'Biochemistry, 2Pathology, University of Graz,
Austria
Aim: Malignant tumors of various tissue origin have previously
been found associated with a characteristic shift in serum IgG
subclasses, consisting in a decrease of%IgGl accompanied by an
increase of %IgG2 relative to total IgG. In view ofthe lack of an
appropriate serological tumor marker for squamous cell carcinoma
of the head and neck (SCC-HN), the diagnostic performance of
this new indirect marker was examined. Methods and results: An
affinity chromatography technique based on IgG binding to
staphylococcus proteins A and G was used for the quantitative
determination ofIgG, IgGl, and IgG2 in sera from 110 SCC-HN
patients and 179 healthy controls. The mean values for %IgGl of
patients and controls were 56.4±0.7 and 63.3±0.5, respectively,
and differed highly significantly (p<0.0005) from each other. Based
on a calculated cut-off (59.9%) the overall diagnostic sensitivity
was 70% with a specificity of 75%. In the postoperative
monitoring patients with recurrent diseases (n=35) were correctly
diagnosed to 83%, and in 15 patients with distant metastases the
sensitivity was 87%. Conclusion: The shift in IgG subclasses as
tissue non specific marker may be of diagnostic value in initial
diagnosis as well as postoperative monitoring of SCC-HN and
evaluating distant metastases.
15.5
Epstein-Barr-Virus-derived plasmids as vectors for the generation of
cytotoxic T-lymphocytes
R. Zeidlerl,B. Wollenberg', E. Kasteibauer', W. Harnmersdimidt2, 'Dep. of Otaoinolaryngology,
LM University ofMunich, 2Is forClinical Moleclar Biology, GSF-Naticmal Research Ceter for
The Epstein Barr-Virus is the only known virus, which is able to
infect and immortalize human B cellswithhigh efficiency in vitro.
We have constructed EBV-derived recombinant plasmids ("mini-
EBV") which are able to immortalize primary human B-
lymphocytes in vitro by transfection. These plasmids carry all the
viral genes necessary for their permanent intracellular maintenance
(latency), but lack most of the genes for the productive lytic
lifespan. Therefore, no virus is produced and secreted.Mini-EBV's
have been constructed in E.Coli using the chromosomal building
technique described by O'Connor et al. (Science 244: 1307, 1989).
This method is advantageous in that any human gene of interest
can be added to mini-EBV plasmids easily. B-lymphocytes which
have been immortalized with Mini-EBV can thus be used as
antigen presenting cells for the presentation ofpeptids derived e.g.
tumor associated or viral proteins. We usedMini-EBV to express
the E6 and E7 oncoproteins from Human Papilloma Virus (HPV)
on immortalized B cells. The purpose ofour investigations is the in
vitro generation of HPV-specific autologous cytotoxic T-
lymphocytes. These T cells may subsequently be used for an
adoptive transfer in the treatment ofHPV-associated laryngeal
papillomatosis.
15.3
Mechanisms responsible for fimctional and signaling defects in
lymphocytes recovered from patients with head and neck cancer
T.L. Whiteside, T.E. Reichert, B. Gastman, H. Rabinowich, University
ofPittsburgh Cancer Institute, USA
It has been documented that lymphocytes recovered from human tumors of the
peripheral blood of patients with advanced malignancies are functionally
compromised. More recently, abnormalities in signaling via the T cell receptor
in T cells and FcyRIII in NK cells obtained from cancer patients have been
described. We have demonstrated that in comparison to normal T
lymphocytes, those isolated from tumor-involved lymph nodes (LNL) or blood
(PBL) of patients with head and neck cancer (HNC) have defects in
expressions and function of signaling molecules, including significantly
decreased expression of TcR-associated ( and e chains, altered expression of
downstream protein tyrosine kinase p53 lek, decreased Ca++ flux as well as
impaired kinase activity following triggcring with anti-CD3 antibodies. Some
of these defects were demonstrable in situ in T cells present in tumor tissues.
Consistently observed decreased expression ofthe ( chain patients' T cells did
not correlate with the nearly normal levels of mRNA for this protein, an
indication that its loss is a post-translational event. LNL in tumor-involved LN
of patients with HNC were shown to contain numerous apoptotic (TUNEL+)
CD3+ lymphocytes in situ. Co-incubation of normal activated T cells or Jurkat
cells with tumor cells induced degradation of the ( chain as well as apoptosis
in a substantial proportion of lymphocytes. Since both fresh and cultured
tumor cells were shown to express FasL, and T cells in tumors were found to
be Fas+, we hypothesize that the Fas-FasL pathway is, at least in part,
responsible for signaling defects and apoptosis induced by the tumor in
lymphocytes found in its milieu. A better understanding of the mechanisms
involved in tumor-induced immunosuppression is necessary in order to be able
revers or prevent functional impairement of lymphocytes in patients with
HNC.
15;6
New insights on adenoviral vectors
P. Yeh, M. Pericaudet, Lab. of Viral Oncology, Inst. Gustave
Roussy, Viliejui.t France
Further deletions of indispensable genes from the backbone ofEl-deleted
adenoviral vectors should decrease their immunogenicity and increase
their biosafety. In this respect, a way to cripple ihe virus is to silence the
E4 locus, a region which regulates the infectious cycle at both the
transcriptional and post-transcriptional levels oflate viral gene expresion.
We thus constructed an EIE4 transcomplementing, 293-derived, cell line
allowing the generation and propagation of EIE4 doubly-deleted viruses.
The biology of these new-generation vectors has been assessed in vitro
and in vivo. We conclude that the additional deletion of E4 translates
into:
- a lower level of viral backbone replication
- a drastic shutoffof late viral gene expression
- no apparent virus-induced cytotoxicity
- an absence of RCA contamination
A tail vein injection of 1-galactosidase-encoding EIE4-deleted viruses to
C57BL/6 lacZ-trangenic mice leads to a much longer persistance of the
viral chromosome in the liver (as a linear, non-methylated entitiy) as
compared with an El-deleted virus. Despite the long-term gene delivery,
the choice ofthe promoter used to drive the expression ofthe transgene is
found to be critical; thus, a liver-specific promoter (rat albumin
promoter) and a viral promoter (LTR from RSV) lead to a stable and a
very transient gene expression, respectively.
Our studies demonstrate the feasibility of Ad-mediated durable gene
transfer to quiescent tissues. Moreover, the cloning capacity of this
vector, which is now extended to 10kb, will facilitate the insertion of
regulatory sequences to fine-tune gene expression.46 Immunology, Gene therapy
15.9
Non-viral delivery of apoptosis inducing genes p53, Bax and
Bcl-x-s
J.L. Coil'2, M.C. Favrot'2, 'Centre Leon Berard, Lyon, 2Inst. Albert
Bonniot, La Tronche, France
p53, Bax and Bcl-x-s are candidates for gene therapy. We chose to
use non viral methods oftransfer and to generate new vectors for
gene targeting.
We first used chCE7 monoclonal antibody directed against
neuroblastoma cells, based on its specificity and capacity of
internalisation, and covalently linked chCE7 to polylysine. In
presence of chloroaquine, chCE7-polylysine-DNA complexes in
vitro uptake was close to 100% in neuroblastoma cells and
specific. However, transfection efficiency was hampered by
degradation of endocytosed particles. This currently improved by
using PEI rather than polylysine
Transferrin added into DNA-TFX complexes was used to analyse
the effect ofp53, Bax and Bcl-x-s in vitro on NSCLC cell lines
H322 and H358. Bax expression killed 70-90% of transfected
cells, whereas p53 only killed 40%. Yet, the transient expression of
the genes in 25% oftransfected cells did not inflect cell growth in
culture, suggesting a poor by-stander killing.
Finally, we tested the efficiency of repeated injections ofBax and
Bcl-x-s naked DNA in vivo. Although transduction efficiency was
extremely low, a surprisingly strong antitumor actIvity was
observed on NSCLC cell lines.
Our results demonstrate the interest ofBox and Bcl-x-s as non viral
vectors in the gene therapy oflung cancer.
15.15
Gene therapy of squamous cell carcinoma of the head and neck by
transfection with the B7.1 Gene
S. Lang'2, T. Whiteside2, R. Zeidler', B. Wollenberg', 'Dept. of ORL,
LM University ofMunich, Germany, 2University ofPittsburgh, USA
Squamous cell carcinoma (SCC) ofthe head and neck are poorly
immunogenic, possibly because of the lack of expression of
co-stimulatory molecules like B7. 1 and B7.2. The objective of our
study was to increase tumor immunogenicity in vitro and in vivo
by transduction of expression plasmids encoding B7. 1 cDNA in
CD80-negative SCC lines. In vitro the transfection of CD80 in
human as well as murine SCC lines ofthe head and neck rendered
these cells strong stimulators of proliferation and cytotoxicity of
allogeneic as well as autologous lymphocytes.
Invivo, in an immunocompetent mouse model (SCC7/C3HIN), the
liposomal transfection of the B7.1 gene into the murine SCC7
tumor improved the quality and quantity of cellular infiltrate and
function. Nevertheless tumor growth could not be significantly
inhibited, as the gene expression was probably to low and to
transient. In a second approach B7 transfected SCC7- tumor cells
were applied as a vaccine. As a result tumor growth could be
inhibited in 4 out of5 mice, being tumor free as compared to mice
inoculated with the parental tumor cells (0% tumor free).
Additionally, all ofthe tumor-free mice subsequently rechallenged
with the wild-type tumor demonstrated partial systemic immunity
as compared to the non-vaccinated control group. In coinclusion,
our in vitro and in vivo data support the potential clinical utility of
B7.1-mediated gene therapy in head and neck cancer, creating
anti-tumor specific immunity.
15.11
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head
and neck squamous cell carcinoma
G.L. Clayman, A.K. El-Naggar, S.M. Lippmann, Y.C. Henderson, M. Frederick, T.J.
Liu, L. Ginsberg, J. Merritt, L. Zumstein, T. Timmons, J.A. Roth, W.K. Hong, P.
Bruso, H. Goepfert, MD Anderson Cancer Center, Houston, USA
Background: Standard therapies of head-and-neck squamous cell carcinoma
often cause profound morbidity and have produced little better survival in 30
years. Wild-type (normal) p53 gene transduction inhibited growth, induced
apoptosis and potentiated irradiation and cytotoxic chemotherapy preclinically.
We tested the safety and efficiency of adenovirus-mediated transfer of wild-
type p53 gene and assessed for clinical activity.
Methods: Patients with advanced recurrent head-and-neck cancer received
dose-escalated direct tumor injections of wild-type p53 (Adp53) in an
adenoviral vector. We carefully monitored patient toxicity and clinical
outcomes. We measured p53 gene transduction via polymerase-chain-reaction
(PCR) and immunohistochemical analyses; biologic endpoints of transduction
via histopathologic, RT-PCR and TUNEL assays; biodistribution of vector via
PCR and viral cultures.
Results: Thirty patients (13 resectable, 17 nonresectable) were treated. All 30
were evaluable for toxicity. No dose-limiting effects of therapy occurred.
Minor adverse events included pain at injection sites and transient fevers. All
patients exhibited an adenovirus typ-5 antibody response (without
hypersensitivity or allergic reactions). Clinical activity was evaluable in the 17
nonsresectable patients - 2 had objective tumor responses; 6 had stable disease;
9 had progressive disease. Biodistribution of vector was detected by PCR in
plasma and serum up to 90 minutes after injections and in voided urine after
1010 PFU and higher doses. We detected transduction in cancer and non-
malignant cells. Tumor-cell transduction occurred despite antibody responses
after repeated cycles. Few transduced carcinoma cells exhibited papooses. We
detected necrosis and papooses induction in tumor specimens with
endogenously mutated or wild-type p53
Conclusions: Patients with recurrent head-and-neck cancer were safely treated
with gene transfer. No dose-limiting toxic effects occurred. Local tumor
inflammatory responses were unaccompanied by negative effects (e.g.,
hypersensitivity) and so may have been beneficial. These results support
further study ofthis approach in solid malignancies.
15.16
A bispecific antibody induces efficient killing of tumor cells -
phase I-trial in patients with HNSCC
B. Wollenberg, B. Schmitt, S. Erndl', S. Lang, H. Lindhofer', E. Kastenbauer,
R. Zeidler, Dept. ofENT, LMU, 'GSF-Research Center, Munich, Germany
Bispecific antibody (BiAb) have been shown to be powerflil tools
to induce T cell mediated antitumor responses both in vitro and in
vivo. We have constructed a bispecific antibody which targets
Ep-CAM present on e.g. head and neck squamous cell cancer with
its one arm and T lymphocytes via CD3 with its second arm.
Incubation of tumor cells with peripheral allogeneic blood
mononuclear cells with this antibody resulted in activation of T
cells and efficient killing ofthe tumor cells. Activated T cells kill
tumor cells in a second round experiment even w/o the addition of
BiAb. PBMCs which have been depleted of
monocytes/macrophages and therefore are reffered to as peripheral
blood lymphocytes (PBL) are much less efficient in tumor cell
killing. This implicates that monocytes/macrophages are activated
by binding to the Fc-gamma part ofthe BiAb and may contribute
to fill T cell activation. This is proven by the induction ofCD25,
40, and 80 on CD14+ cells. Our results have lead to the initiation
of a clinical phase-I-trial, using BiAb for the killing of residual
tumor cells in a minimal residual disease situation to target and
eliminate metastases in HNSCC. The antibody has been well
tolerated to date and systemic antibody response towards the
tumor could be established.Immunology, Gene therapy 47
15.17
Gene therapy of HNSCC with liposomal mediated h-IL2 plasmids - phase 1-
study
C. Pauli, K. Naujoks', H. Mundl',S.Lang, R. Zeidler, E. Kastenbauer, B. Wollenberg,
Dept. of ORL, LM University of Munich, 'Boehringer Mannheim Therapeutica,
Penzberg, Germany
Recombinant 1L-2 protein has been approved for the treatment of
renal cell carcinoma and has shown efficacy in other human
tumors. The clinical use ofrIL-2 is limited by common and serious
side effects after systemic administration. Local production oflow
levels of 11-2=20 should produce limited or no systemic side
effects. Squamous cell carcinoma of the head and neck is an
adequate target for local therapy since it is usually localized to the
tumor and its draining lymph nodes, which are readily accessible
for direct intratumoral injection.
Since August 1997 we have initiated a monocenter, single blind,
placebo-controlled, dose-rising study ofthe safety art tolerability
of a single intratumoral injection of hIL-2 plasmid at four dose
levels formulated in DOTMA/Chol in patients with primary
untreated head and neck squamous cell cancer (HNSCC) TNM
stage II - IV. This work is performed in collaboration with
Boehringer Mannheim and Gene Medicine, USA. To date the
treatment has been well tolerated. To document the expression of
the IL-2 gene in squamous cell carcinoma molecular biologic,
histologic and immunohistochemical methods were applied. The
safety profile was assessed by reporting ofclinical adverse events,
physical examination, vital signs (temperature, heart rate, blood
pressure and respiratory rate), clinical laboratory tests
(hematology, blood chemistry, urinanalysis) and IL-2 antibodies in
serum.
15.18
A novel ERK-pathway inhibitor (PD098059) arrests invasion and growth
of HNSCC in a murine model
C. Simon, J. Hicks, A. Nemechek, R. Mehta, B.W. OMalley Jr., C. Flaitz, H.
Goepfert, D. Boyd, MD Anderson Cancer Center, Houston, USA
The prognosis for patients with HNSCC is intimately linked to
invasion ofadjacent tissues. Thus, inhibition ofprotease expression
in HNSCC via interference with signal transduction pathways may
reduce invasive properties and improve survival. Recently, we have
shown that a specific ERK-pathway inhibitor ( PD 098059 ) arrests
invasion ofUM-SCC1 cells in-vitro. We therefore investigated the
effect ofPD 098059 on this cell line in-vivo. Using a quantitative
orthotopic murine model, stepwise invasion ofthe floor-of-mouth
and tongue were evaluated after subcutaneous tumour cell
injection. Intralesional administration of PD 098059 using
liposomes as a carrier was performed over a 25 day period (every
5 days with 15mM final concentration). Tumor growth arrest and
attenuation of tumor invasion occurred in 3 of 4 treated mice;
while tumor advanced into the genioglossus muscle in 4 of 5
control mice.
Therefore the inhibition of the ERK-signal transduction pathway
may become a powerful therapeutic adjuvant in combating invasion
ofHNSCC.